Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.

NACompletedINTERVENTIONAL
Enrollment

422

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 9, 2018

Study Completion Date

May 9, 2018

Conditions
Hepatitis CHIVAIDSSubstance Use
Interventions
OTHER

Control Group

"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."

BEHAVIORAL

Care Facilitation Group

"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."

Trial Locations (11)

10025

Mount Sinai - St. Luke's Roosevelt Hospital Center, New York

15213

University of Pittsburgh Medical Center Presbyterian / Pittsburgh AIDS Center for Treatment, Pittsburgh

19102

Hahnemann University Hospital, Philadelphia

21287

Johns Hopkins Hospital / Moore Clinic, Baltimore

30322

Grady Memorial Hospital / Ponce de Leon Center, Atlanta

33136

Jackson Health System Adult HIV Outpatient Clinics / University of Miami, Miami

35294

University Hospital at University of Alabama at Birmingham, Birmingham

60612

John H. Stroger Jr. Hospital of Cook County, Chicago

75390

University of Texas Southwestern, Dallas

90502

Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance

02118

Boston University Medical Center, Boston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Jackson Health System

OTHER

collaborator

Grady Memorial Hospital

OTHER

collaborator

St. Luke's-Roosevelt Hospital Center

OTHER

collaborator

University of Texas

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University Hospital Birmingham

OTHER

collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Hahnemann University Hospital

OTHER

collaborator

Cook County Health

OTHER_GOV

collaborator

Boston University

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of Miami

OTHER

collaborator

University of California, San Francisco

OTHER

lead

Columbia University

OTHER

NCT02641158 - Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S. | Biotech Hunter | Biotech Hunter